Following Ravicti Win in UCD, Hyperion Seeks $59.7M for HE
By Marie Powers
Monday, March 11, 2013
One month after gaining FDA approval for Ravicti (glycerol phenylbutyrate) in the chronic management of certain urea cycle disorders (UCDs), orphan disease specialist Hyperion Therapeutics Inc. upsized a public offering of about 2.9 million shares of common stock, priced at $20.75, seeking to raise $59.7 million.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.